Author + information
- Fei Chen,
- Jingchao Lu and
- Fan Liu
This study sought to investigate the effects of atorvastatin on late recurrence after catheter ablation of paroxysmal atrial fibrillation.
120 patients with paroxysmal atrial fibrillation who underwent circumferential pulmonary vein isolation(CPVI) were randomly divided into atorvastatin group (n=60) and control group (n=60). Both groups received routine medical treatment. Atorvastatin group, the patients were administered atorvastatin for 12 months after CPVI; control group, the patients were not given statins. The late recurrence rate and atrial fibrillation load were observed by telephone follow-up, regular electrocardiogram, Holter monitoring and echocardiography. Blood sample were collected before and 3, 6, 12 months after CPVI. The inflammatory markers including high-sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6) were measured.
All patients were followed up for 12 months, and the recurrence rates of atorvastatin group and control group were 13.3% and 23.3% respectively. But there was no statistical difference between the two groups (P=0.157). Compared with the control group, the atrial fibrillation load was significantly reduced in atorvastatin group (P<0.05). Before and 12 months after CPVI, there was no significant difference in left atrial diameter between the two groups (P>0.05). Compared with the control group, the levels of inflammatory factors (hs-CRP, IL-6) were significantly lower (P<0.05) in atorvastatin group.
Atorvastatin treatment did not decrease the late recurrence in patients with paroxysmal atrial fibrillation after catheter ablation, but it can reduce the inflammatory reaction and atrial fibrillation burden.